18F-FDG PET/MRI用于儿童及青少年霍奇金淋巴瘤分期与中期疗效评估:以18F-FDG PET/CT为参考标准的前瞻性研究
该前瞻性研究纳入24例儿童及青少年霍奇金淋巴瘤患者,在初始分期和疗效评估时均行18F-FDG PET/CT与PET/MRI检查,以PET/CT为参考标准比较PET/MRI的诊断性能。校正感知误差后,PET/MRI分期敏感度100%、特异度99.5%,疗效评估敏感度83.3%、特异度100%,Ann Arbor分期一致 perfect(κ=1.0),Deauville评分一致 excellent(κ=0.835)。
要点
- 校正感知误差后,PET/MRI对霍奇金淋巴瘤分期的敏感度100%、特异度99.5%。
- 疗效评估中PET/MRI敏感度83.3%、特异度100%,Deauville评分一致性好(κ=0.835)。
- PET/MRI与PET/CT的Ann Arbor分期完全一致(κ=1.0),有望减少辐射剂量。
核心结论
- 18F-FDG PET/MRI是儿童霍奇金淋巴瘤分期和疗效评估中有前景的PET/CT替代方法。
研究设计与样本
- 前瞻性、连续纳入2015至2016年24例组织学证实的霍奇金淋巴瘤患者,平均年龄15.4岁(范围8-19.5岁)。
- 初始分期24例、疗效评估21例均行18F-FDG PET/CT和18F-FDG PET/MRI,以PET/CT为参考标准。
- 回顾性将不一致分类为感知错误或技术错误,并通过去除感知错误校正PET/MRI和PET/CT。
主要发现
- 校正后分期PET/MRI对淋巴结和结外病灶合并分析的敏感度为100%(95%CI,96.7%-100%),特异度为99.5%(95%CI,98.3%-99.9%)。
- 校正后疗效评估PET/MRI的敏感度为83.3%(95%CI,36.5%-99.1%),特异度为100%(95%CI,99.2%-100%)。
- PET/CT与PET/MRI的改良Ann Arbor分期一致性完美(κ=1.0,P=0.000)。
- PET/MRI与PET/CT的Deauville评分一致性极好(κ=0.835,P=0.000)。
关键数值与推荐
- 校正后分期PET/MRI敏感度100%(95%CI,96.7%-100%),特异度99.5%(95%CI,98.3%-99.9%)。
- 校正后疗效评估PET/MRI敏感度83.3%(95%CI,36.5%-99.1%),特异度100%(95%CI,99.2%-100%)。
- 改良Ann Arbor分期一致性κ=1.0(P=0.000);Deauville评分一致性κ=0.835(P=0.000)。
临床怎么用
- 在儿童及青少年霍奇金淋巴瘤中,18F-FDG PET/MRI可用于分期和疗效评估,有望降低辐射剂量。
- 判读时需注意感知误差,校正后PET/MRI与PET/CT的分期和Deauville评分一致性高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment regimens for pediatric Hodgkin lymphoma (HL) depend on accurate staging and treatment response assessment, based on accurate disease distribution and metabolic activity depiction. With the aim of radiation dose reduction, we compared the diagnostic performance of 18F-FDG PET/MRI with a 18F-FDG PET/CT reference standard for staging and response assessment. Methods: Twenty-four patients (mean age, 15.4 y; range, 8-19.5 y) with histologically proven HL were prospectively and consecutively recruited in 2015 and 2016, undergoing both 18F-FDG PET/CT and 18F-FDG PET/MRI at initial staging (n = 24) and at response assessment (n = 21). The diagnostic accuracy of 18F-FDG PET/MRI for both nodal and extranodal disease was compared with that of 18F-FDG PET/CT, which was considered the reference standard. Discrepancies were retrospectively classified as perceptual or technical errors, and 18F-FDG PET/MRI and 18F-FDG PET/CT were corrected by removing perceptual error. Agreement with Ann Arbor staging and Deauville grading was also assessed. Results: For nodal and extranodal sites combined, corrected staging 18F-FDG PET/MRI sensitivity was 100% (95% CI, 96.7%-100%) and specificity was 99.5% (95% CI, 98.3%-99.9%). Corrected response-assessment 18F-FDG PET/MRI sensitivity was 83.3% (95% CI, 36.5%-99.1%) and specificity was 100% (95% CI, 99.2%-100%). Modified Ann Arbor staging agreement between 18F-FDG PET/CT and 18F-FDG PET/MRI was perfect (κ = 1.0, P = 0.000). Deauville grading agreement between 18F-FDG PET/MRI and 18F-FDG PET/CT was excellent (κ = 0.835, P = 0.000). Conclusion:18F-FDG PET/MRI is a promising alternative to 18F-FDG PET/CT for staging and response assessment in children with HL.
引用
- Verhagen MV, Menezes LJ, Neriman D, et al. 18F-FDG PET/MRI for Staging and Interim Response Assessment in Pediatric and Adolescent Hodgkin Lymphoma: A Prospective Study with 18F-FDG PET/CT as the Reference Standard. J Nucl Med. 2021. PMID: 33608429. doi:10.2967/jnumed.120.260059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。